Form 4: Halliburton EVP Eric Carre Reports Sale of Common Stock
SEC Form 4 Filing
Halliburton's EVP & Chief Financial Officer, Eric Carre, reported the sale of common stock on March 14, 2025, under a pre-arranged trading plan.
Summary
- Eric Carre, EVP & Chief Financial Officer of Halliburton, reported a transaction involving the sale of common stock on March 14, 2025.
- The sale of 51,179 shares was executed at a price of $25 per share.
- Following the transaction, Carre directly owns 127,101.377 shares of Halliburton common stock.
- The sale was conducted under a Rule 10b5-1 trading plan adopted on November 12, 2024.
- Carre also holds options to buy common stock, with various expiration dates and exercise prices.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the document simply reports a transaction. The sale was pre-planned under a 10b5-1 trading plan, suggesting it's part of a routine financial strategy rather than a reaction to company performance.
Industry Context
Executive stock sales are a common occurrence in publicly traded companies. They can be part of a pre-planned diversification strategy or for personal financial planning. The use of a 10b5-1 trading plan suggests the sale was planned in advance to avoid any accusations of insider trading.
Comparison to Industry Standards
- Executive compensation and stock ownership are closely monitored in the oilfield services industry.
- Halliburton's executive compensation practices are likely benchmarked against peers such as Schlumberger and Baker Hughes.
- Stock ownership guidelines for executives are common, encouraging alignment with shareholder interests.
- Rule 10b5-1 trading plans are a standard tool used by executives across various industries to manage stock sales.
Stakeholder Impact
- The stock sale by an executive could be perceived negatively by some shareholders, although the use of a 10b5-1 plan mitigates concerns about insider trading.
- The transaction has a minimal direct impact on employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 12/07/2016 | Date of option grant with exercise price of $53.54 and expiration date of 12/07/2026. |
| 12/06/2017 | Date of option grant with exercise price of $43.38 and expiration date of 12/06/2027. |
| 12/05/2018 | Date of option grant with exercise price of $31.44 and expiration date of 12/05/2028. |
| 01/04/2016 | Date of option grant with exercise price of $34.48 and expiration date of 01/04/2026. |
| 11/12/2024 | Date the Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 03/14/2025 | Date of the transaction involving the sale of common stock. |
| 03/17/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.